**H₃ histamine receptor antagonist pitolisant reverses some subchronic disturbances induced by olanzapine in mice**

Magdalena Dudek¹ · Kamil Kuder² · Marcin Kołaczkowski³ · Adrian Olczyk⁴ · Elżbieta Źmudzka⁵ · Aleksandra Rak⁵ · Marek Bednarski⁵ · Karolina Pytka¹ · Jacek Sapa⁵ · Katarzyna Kieć-Kononowicz²

Received: 18 February 2016 / Accepted: 16 May 2016 / Published online: 24 May 2016 © The Author(s) 2016. This article is published with open access at Springerlink.com

**Abstract** The use of atypical antipsychotic drugs like olanzapine is associated with side effects such as sedation and depression-like symptoms, especially during the initial period of the use. It is believed that the occurrence of these undesirable effects is mainly the result of the histamine H₁ receptors blockade by olanzapine. In addition, use of olanzapine increases the level of triglycerides in the blood, which correlates with growing obesity. The aim of this study was to investigate the influence of pitolisant – H₃ histamine antagonist – on subchronic olanzapine-induced depression-like symptoms, sedation and hypertriglyceridemia. Forced swim test was conducted to determine depressive-like effect of olanzapine and antidepressive-like activity during the co-administered pitolisant. The test was performed after the first and fifteenth day of the treatment of the mice. The spontaneous activity of the mice was measured on the fourteenth day of the treatment with a special, innovative RFID-system (Radio-frequency identification system) – TraffCiCage (TSE-Systems, Germany). Triglyceride levels were determined on the sixteenth day of the experiment after 15 cycles of drug administration. Daily olanzapine treatment (4 mg/kg b.w., i.p., d.p.d) for 15 days significantly induces sedation (p < 0.05) and prolongs immobility time in forced swim tests (FST) in mice (p < 0.05); and also elevates the level of triglycerides (p < 0.05). Administration of pitolisant (10 mg/kg b.w., i.p.) subsequent to olanzapine normalizes these adverse effects. This study presents a promising alternative for counteracting some behavioral changes and metabolic disturbances which occur in the early period of treatment with antipsychotic drugs.

**Keywords** Pitolisant · Olanzapine · Sedation · Depression-like symptoms · Locomotor activity · Triglycerides

**Introduction**

Olanzapine is one of the most commonly used atypical drugs for schizophrenia (Podogrodzka and Jarema 2010), and one of the strongest antagonists of the H₁ histamine receptors (H₁R) (Richelson and Souder 2000). The use of atypical antipsychotic drugs like olanzapine is associated with some side effects, such as sedation and depression-like symptoms, especially in the initial period of the use (Podogrodzka and Jarema 2010). Atypical antipsychotics such as olanzapine may also increase the level of triglycerides in the blood (Albaugh et al. 2011; Misiak et al. 2014), which correlates with the development of obesity during the treatment. This very unfavorable side effect may be related to H₁R (Reynolds and Kirk 2010) or H₃ receptors (Deng et al. 2010). Data from literature confirm the sedative effects of olanzapine in rodents, which increases proportionally to the dose (Weston-Green et al. 2011). It is believed that the occurrence of these undesirable effects may be
connected with the blockade of H₃R (Miller 2004) and cholinergic M₁ receptor (M₁R) (Kane and Sharif 2008). Therefore, the search for solutions to the problems of sedation and depression-like symptoms occurring in the initial period of atypical antipsychotics use is very significant. Due to the belief, that simple blockade of histamine action, by H₁R antagonism may be responsible for these effects, the possible solution might be connected with H₂R ligands. In our research, we have explored one of the H₂R antagonists – Pitolisant (Wakix®) - as a potential target to minimize the adverse effects accompanying antipsychotic treatment.

The H₃ receptor is a pre-synaptic autoreceptor that inhibits synthesis and release of the histamine, and simultaneously a heteroreceptor that inhibits other neurotransmitters such as serotonin, noradrenaline and acetylcholine (Deng et al. 2010). It belongs to the G-protein-coupled receptor (GPCR) family, with a complex structure and a large number of isoforms (Lovenberg et al. 1999; Hancock et al. 2003; Bakker 2004). The H₃R are mainly expressed in the central nervous system (CNS), especially in the areas connected with sleep, cognition and homeostatic regulation (Haas et al. 2008). Blockade of the H₃R in the central nervous system results in increased synthesis and disinhibition of the histamine release (Brabant et al. 2013), a phenomenon explored further in this study.

Many different ligands of H₃R have been investigated in recent years, and studies are still in progress (Łazewska and Kieć-Kononowicz 2010; Łażewska and Kieć-Kononowicz 2014). One of the most heavily researched compounds is Pitolisant, which is currently being tested in the third phase of clinical trials (Łazewska and Kieć-Kononowicz 2014). Pitolisant is a selective inverse agonist for the H₃R, which enhances histaminergic activity in the brain of mice (Ligneau et al. 2007). Its efficacy and safety in the treatment of narcolepsy have been recently documented in a large European multicentre double-blind, randomised, parallel-group controlled trial (Dauvilliers et al. 2013). Pitolisant’s wake-promoting activity was evidenced in excessive diurnal sleepiness of patients with narcolepsy, Parkinson’s disease or Obstructive Sleep Apnea/Hypopnea. The activity is characterized by a mean decrease on the Epworth Sleepiness Scale (ESS) by about five units (Schwartz 2011). Moreover, the procognitive activity of Pitolisant makes it a potential target in diseases with cognitive deficits such as schizophrenia, dementia or ADHD (attention deficit hyperactivity disorder) (Schwartz 2011). Without question, its high therapeutic potential is the reason why we chose this compound for our research.

The aim of this study was to investigate the influence of pitolisant – an H₃ histamine antagonist - on subchronic olanzapine-induced depression-like symptoms, sedation and hypertriglyceridemia.

Materials and methods

Animals

Adult female Albino Swiss mice weighing 20–22 g were used in the study. They were kept in environmentally controlled rooms, in standard cages lit by an artificial light for 12 h each day. Animals had free access to food and water except for the time of the acute experiment. The randomly established experimental groups consisted of 12 mice. The groups were used in the forced swim test (6 mice) and in the locomotor studies (6 mice). Spontaneous activity was performed one day before the forced swim test in a subchronic treated group of animals (6 mice). Triglyceride levels were determined only in the mice subjected to locomotor studies (6 mice). All animal care and experimental procedures were carried out in accordance with European Union and Polish legislation acts concerning animal experimentation, and approved by the Local Ethics Committee at the Jagiellonian University in Cracow.

Experiment methods

Forced swim test (FST)

The forced swim test was conducted according to the method described in the available literature (Porsolt et al. 1977; Pytka et al. 2015a; Pytka et al. 2015b). Mice were forced to swim individually in the glass cylinders (height 25 cm, diameter 10 cm) filled with 10 cm of water at a temperature of 23–25 °C. The animals were placed into the cylinders for 6 min, and the total duration of their immobility was recorded after a 2-min initial period. The test was performed after the first and fifteenth day of the treatment of the mice (the first day after administration – acute treatment, or the sixteenth day after the fifteenth administration – subchronic treatment).

Locomotor activity

Locomotor activity was recorded with an Opto M3 multichannel activity monitor (MultiDevice Software v1.3, Columbus Instruments, USA) according to the method described by Pytka et al. (Pytka et al. 2015c; Pytka et al. 2016). After being placed into the cages individually, the mice had their activity evaluated between the 2nd and the 6th minute. The time period chosen corresponded with the time interval considered in the FST. Locomotor activity was evaluated as the distance travelled by the animals while attempting to climb upward. The test was performed after the first and fifteenth day of the treatment of the mice (the first day after administration – acute treatment, or the sixteenth day after the fifteenth administration – subchronic treatment).
Spontaneous activity

The spontaneous activity of the mice was measured on the fourteenth day of the treatment with a special, innovative RFID-system (Radio-frequency identification system) – TraffICage (TSE-Systems, Germany). The test was conducted according to the method described in the literature (Dudek et al. 2015a; Dudek et al. 2015b; Dudek et al. 2016). The animals had the transmitter (RFID) subcutaneously implanted, which tracked the time they spent in different areas of the cage. The data obtained were then grouped in a special computer program. Spontaneous activity was measured starting from the fourteenth day of the treatment at 1:00 pm to the fifteenth day at 9:00 am. The mice were housed in cages in threes, with food and water available ad libitum.

Biochemical analysis

Triglyceride levels were determined on the sixteenth day of the experiment after 15 cycles of drug administration. The mice were euthanized by cervical dislocation. The blood was collected after decapitation and then centrifuged at 1200 rtf to obtain the serum. To determine triglyceride levels in the serum, standard enzymatic spectrophotometric tests (Biomaxima S.A. Lublin, Poland) were used. The substrate was decomposed with enzymes appropriate for the relevant product, and converted to a colored compound. The coloration was proportional to the concentration. Absorbance was measured at a wavelength of 500 nm.

Statistical analysis

The results obtained were analysed using a one-way analysis of variance (ANOVA), followed by a Dunnet post-hoc test, with the significance level set at 0.05 (FST and locomotor activity tests or triglyceride levels) or by a Multiple t-test under the assumption that all rows were sampled from populations with the same scatter (spontaneous activity test). The outcomes were expressed as the means ± standard error of the mean (SEM). Graph Pad Prism 6.0 was used for data analysis.

Drugs, chemical reagents and other materials

Olanzapine or pitolisant were suspended in 1 % Tween 80. The compounds or vehicle were administered...
intraperitoneally (i.p.) 30 min prior to the acute experiment. In the pitolisant + olanzapine group, pitolisant was administered 15 min before olanzapine. Subchronic treatment was done at about 9:00 am (0.2 ml Tween to control group, pitolisant - 10 mg/kg b.w. to pitolisant group, olanzapine - 2 mg/kg b.w. to olanzapine group, pitolisant- 10 mg/kg b.w. and olanzapine after 15 min- 2 mg/kg b.w. to pitolisant + olanzapine group) and at about 1:00 pm (olanzapine group and pitolisant + olanzapine group). The volume of the vehicle or the drug solutions was 10 ml/kg.

Pitolisant was tested at dose 10 mg/kg b.w. According the literature (Brabant et al. 2013; Uguen et al. 2013), at this dose, it’s active but lacks the adverse effects. Olanzapine was tested at dose $2 \times 2$ mg/kg b.w., which, according the literature data (Albaugh et al. 2006; Kim et al. 2014), might induce metabolic disorders in rodents. This dose is also suitable for the observation of decreasing in locomotor activity after olanzapine in rodents (Klingerman et al. 2014). Additionally, due to a much shorter half life of olanzapine in rodents compared to man (van der Zwaal et al. 2008; Liebig et al. 2010), this dose was shown to be appropriate to model pharmacodynamic effects of olanzapine in rodents (Kapur et al. 2003; Liebig et al. 2010). The olanzapine was delivered by Adamed Group (Pieńków, Poland). The Pitolisant was synthesized at the Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, Cracow, Poland.

**Result**

**Depression-like symptoms**

Pitolisant administered once, and for 15 consecutive days at a dose of 10 mg/kg b.w. did not significantly affect the duration of immobility in the forced swim test in mice. The results are shown in Figs. 1a and c. This compound had also no effect on locomotor activity; neither after one nor after fifteen administrations in mice. The results are presented in Figs. 1b and d.

Olanzapine administered to the mice once at a dose of 2 mg/kg b.w., and for 15 days a dose $2 \times 2$ mg/kg b.w. significantly increased the duration of immobility in the forced swim test in comparison to the control group. The results are shown in Fig. 1a and c. Olanzapine also significantly reduced locomotor activity. The result are shown in Fig. 1b and d.

The administration of pitolisant a single dose of 10 mg/kg 30 min before a single dose of olanzapine (2 mg/kg b.w.) also significantly affected immobility time in the FST. Subsequent administration of the aforementioned drug sequence in mice statistically significantly increased the duration of immobility in comparison to the time determined in the control group in the FST. It decreased locomotor activity as well. In contrast, the results obtained in subchronic treatment after fifteen administration.
administrations of both drugs (pitolisant 10 mg/kg b.w., and after 30 min olanzapine 2 mg/kg b.w., and again after 4 h olanzapine 2 mg/kg b.w.) showed that the administration of pitolisant followed by that of olanzapine equalized the locomotor activity in mice; in comparison to the level of motility in the control group, to which only pitolisant was administered (Fig. 1d). More importantly, this combination of drugs significantly reduced immobility time to the level obtained in the control group in the forced swim test in mice [one-way ANOVA; $F_{(3,20)} = 4.226, P = 0.0181$] (Fig. 1c).

**Spontaneous activity**

The control group of mice showed increased motor activity after dark, while during the day their motility was reduced. Both a single administration of olanzapine and its subchronic administration resulted in a statistically significant reduction of spontaneous mobility as compared to the control group in both phases of the day - during the first hour of observation (the bright phase), and from the fifth to the eighth hour of observation (the dark phase). The results are shown in Fig. 2a. Administration of the pitolisant did not significantly affect spontaneous activity in the mice. In the study, the 20-h mobility of the mice treated with pitolisant (10 mg/kg) was very close to the mobility of the mice in the control group, which received only the solvent (1% Tween 80). The results are shown in Fig. 2b. In the group treated with olanzapine and pitolisant together, the mobility was indeed impaired - in the first hours after the second dose of olanzapine, the mice showed reduced motility compared to the control group, but at the end of the dark phase and the following light phase, the mobility was significantly increased. The results are shown in Fig. 2c. When comparing the results of the 20-h observation of spontaneous mobility of the group receiving olanzapine, and the group receiving olanzapine plus pitolisant, it can be said that the addition of pitolisant significantly increases the motility of the mice in the dark phase and the light phase that follows. The results are shown in Fig. 2d. However, there was significant compensation for the reduced motility of the olanzapine-treated group in the dark phase, i.e. the natural phase of very heavy activity in the mice.

**Triglyceride levels**

Intraperitoneal administration of olanzapine at a dose $2 \times 2$ mg/kg b.w. for 14 days resulted in a statistically significant increase in the level of triglycerides in the mice serum. In the group which was administered pitolisant (10 mg/kg b.w.) together with olanzapine, the triglyceride level was comparable to that in the control mice. Pitolisant administered alone had no effect on the levels of triglycerides in mice. Figure 3 shows the results.

**Discussion**

In the current study, the sub-chronic administration of pitolisant in combination with olanzapine resulted in reduction of the immobility time in the FST in mice to the level determined in the control group, which limits depression-like symptoms. Moreover, pitolisant compensated for the spontaneous activity disturbances observed in the olanzapine-treated group. Thus, our results confirm the beneficial effects of the combined used for these compounds.

Studies using various $H_3R$ ligands have shown that these compounds can favorably affect the levels of triglycerides in animals (Hancock and Brune 2005; Malmlöf et al. 2006). Atypical antipsychotics such as olanzapine may increase the level of triglycerides in the blood (Albaugh et al. 2011; Misiak et al. 2014), which correlates with the development of obesity during the treatment. This very unfavorable side effect may be related to the influence on the $H_3R$ (Reynolds and Kirk 2010).
or H₃R (Deng et al. 2010). A drug-induced decrease in H₁R activity may reduce the histamine tone via the H₃autoreceptors, contributing to the weight gain problem. In addition, atypical antipsychotics may affect food intake by influencing serotonin, noradrenaline and acetylcholine release via interactions with the H₂R (Deng et al. 2010). The observed results confirm that the increased response to the histamine by using pitolisant may remove some metabolic disturbances induced by the administration of olanzapine, such as increased triglyceride levels in the serum. This fact is extremely relevant due to the serious adverse metabolic effects which develop in patients treated with atypical neuroleptics.

It is important to mention that there are no reports on the influence of pitolisant on triglyceride levels in literature. Moreover, there is no information available on the combined use of olanzapine and pitolisant in literature to date. Undoubtedly, our preliminary studies with mice show that this is an interesting combination of drugs. Based on the information available, we only know that the co-administration of olanzapine and pitolisant to healthy volunteers does not significantly change the detected plasma level of the drugs in comparison with their individual administration (Schwartz 2011). Additionally, taking into account the results of the Porsolt test and the following motility measurement, we can unequivocally conclude that pitolisant can reduce the olanzapine-induced sedation and depression–like symptoms.

Conclusion

The observed results confirm that in patients treated with olanzapine who experience unacceptable, adverse effects such as excessive sedation or depression–like symptoms, the administration of pitolisant can be attempted. Moreover, it can be further explored whether this combination of drugs is able to reduce or delay the onset of metabolic disorders induced by olanzapine in patients. The presented preliminary study gives a promising alternative for counteracting some antipsychotic-associated behavioral and metabolic complications, and definitely needs further investigation.

Acknowledgments This work was supported by statutory funds from the Faculty of Pharmacy, Jagiellonian University Medical College, Krakow, Poland.

The authors wish to gratefully acknowledge Teresa Dobrut, Agnieszka Niedbał and Maria Kaleta for their technical assistance.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

Albaugh VL, Henry CR, Bello NT, et al. (2006) Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obesity (Springer) 14:36–51. doi:10.1038/oby.2006.6
Albaugh VL, Singareddy R, Mauger D, Lynch CJ (2011) A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers. PLoS One 6: e22662. doi:10.1371/journal.pone.0022662
Bakker RA (2004) Histamine H3-receptor isomers. Inflamm Res 53: 509–516. doi:10.1007/s00011-004-1286-9
Brabant C, Charlier Y, Tirelli E (2013) The histamine H3-receptor inverse agonist pitolisant improves fear memory in mice. Behav Brain Res 243:199–204. doi:10.1016/j.bbr.2012.12.063
Dauvilliers Y, Bassetti C, Lammers GJ, et al. (2013) Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol 12:1068–1075. doi:10.1016/S1474-4422(13)70225-4
Deng C, Weston-Green K, Huang X-F (2010) The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain? Prog Neuro-Psychopharmacol Biol Psychiatry 34:1–4. doi:10.1016/j.pnpbp.2009.11.009
Dudek M, Knutelska J, Bednarski M, et al. (2015a) A comparison of the anorectic effect and safety of the Alpha2-adrenoceptor ligands Guanfacine and Yohimbine in rats with diet-induced obesity. PLoS One 10:e0141327. doi:10.1371/journal.pone.0141327
Dudek M, Marcinkowska M, Buckley A, et al. (2015b) Idalopirdine - a small molecule antagonist of 5-HT6 with therapeutic potential against obesity. Metab Brain Dis 30:1487–1494. doi:10.1007/s11011-015-9736-3
Dudek M, Knutelska J, Bednarski M, et al. (2016) Pyrrolidin-2-one derivatives may reduce body weight in rats with diet-induced obesity. Eur J Pharmacol 776:146–155. doi:10.1016/j.ejphar.2016.02.047
Haas HL, Sergeeva OA, Selbach O (2008) Histamine in the nervous system. Physiol Rev 88:1183–1241. doi:10.1152/physrev.00043.2007
Hancock AA, Brune ME (2005) Assessment of pharmacology and potential anti-obesity properties of H3 receptor antagonists/inverse agonists. Expert Opin Investig Drugs 14:223–241. doi:10.1517/13543784.14.3.223
Hancock AA, Esbenshade TA, Krueger KM, Yao BB (2003) Genetic and pharmacological aspects of histamine H3 receptor heterogeneity. Life Sci 73:3043–3072
Kane JM, Sharif ZA (2008) Atypical antipsychotics: sedation versus efficacy. J Clin Psychiatry 69(Suppl 1):18–31
Kapur S, VanderSpek SC, Brownelee BA, Nobrega JN (2003) Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305:625–631. doi:10.1124/jpet.102.046987
Kim H, Park M, Lee S-K, et al. (2014) Phosphorylation of hypothalamic AMPK on serine(485/491) related to sustained weight loss by alpha-lipoic acid in mice treated with olanzapine. Psychopharmacology 231:4059–4069. doi:10.1007/s00213-014-3540-3
Klingerman CM, Stipanovic ME, Bader M, Lynch CJ (2014) Second-generation antipsychotics cause a rapid switch to fat oxidation that is required for survival in C57BL/6 J mice. Schizophr Bull 40:327–340. doi:10.1093/schbul/sbu196
Łazewska D, Kieć-Kononowicz K (2010) Recent advances in histamine H3 receptor antagonists/inverse agonists. Expert Opin Ther Pat 20: 1147–1169. doi:10.1517/13543776.2010.590346
Łazewska D, Kieć-Kononowicz K (2014) New developments around histamine H(3) receptor antagonists/inverse agonists: a patent review (2010 - present). Expert Opin Ther Pat 24:89–111. doi:10.1517/13543776.2014.848197
Liebig M, Gossel M, Pratt J, et al. (2010) Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625. Obesity (Silver Spring) 18:1952–1958. doi:10.1038/oby.2010.17

Ligneau X, Perrin D, Landais L, et al. (2007) BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: preclinical pharmacology. J Pharmacol Exp Ther 320:365–375. doi:10.1124/jpet.106.111039

Lovenberg TW, Roland BL, Wilson SJ, et al. (1999) Cloning and functional expression of the human histamine H3 receptor. Mol Pharmacol 55:1101–1107

Malmlöf K, Golozoubova V, Peschke B, et al. (2006) Increase of neuronal histamine in obese rats is associated with decreases in body weight and plasma triglycerides. Obesity (Silver Spring) 14:2154–2162. doi:10.1038/oby.2006.252

Miller DD (2004) Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry 6:3–7

Misiak B, Frydecka D, Lacznatiński L, et al. (2014) Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients. Eur J Clin Pharmacol 70:1433–1441. doi:10.1007/s00228-014-1762-2

Podogrodzka M, Jarema M (2010) Practical aspects of the use of olanzapine in the treatment of schizophrenia and bipolar disorders. Psychiatry 7:180–188

Porsolt RD, Bertin A, Jalfre M (1977) Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn thérapie 229:327–336

Pytka K, Partyka A, Jastrzębska-Więsek M, et al. (2015a) Antidepressant- and anxiolytic-like effects of new dual 5-HT1a and 5-HT7 antagonists in animal models. PLoS One 10:e0142499. doi:10.1371/journal.pone.0142499

Reynolds GP, Kirk SL (2010) Metabolic side effects of antipsychotic drug treatment—pharmacological mechanisms. Pharmacol Ther 125:169–179. doi:10.1016/j.pharmthera.2009.10.010

Richelson E, Souder T (2000) Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 68:29–39

Schwartz J-C (2011) The histamine H3 receptor: from discovery to clinical trials with pitolisant. Br J Pharmacol 163:713–721. doi:10.1111/j.1476-5381.2011.01286.x

Uguen M, Perrin D, Belliard S, et al. (2013) Preclinical evaluation of the abuse potential of pitolisant, a histamine H3 receptor inverse agonist/antagonist compared with modafinil. Br J Pharmacol 169:632–644. doi:10.1111/bph.12149

Van der Zwaal EM, Luijendijk MCM, Adan RAH, la Fleur SE (2008) Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution. Eur J Pharmacol 585:130–136. doi:10.1016/j.ejphar.2007.11.078

Weston-Green K, Huang X-F, Deng C (2011) Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats. Behav Brain Res 217:337–346. doi:10.1016/j.bbr.2010.10.039